Varenicline and the Evaluation of Neuropsychiatric Adverse Events in Smokers

被引：2
|
作者：
O'Malley, Stephanie S. [1 ]
机构：
[1] Yale Univ, Sch Med, Div Subst Abuse Res, New Haven, CT 06517 USA
来源：
BIOLOGICAL PSYCHIATRY | 2011年 / 69卷 / 11期
关键词：
DEPRESSION; SMOKING;
D O I：
10.1016/j.biopsych.2011.04.012
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：1017 / 1018
页数：2
相关论文
共 50 条
  • [31] Neuropsychiatric safety and efficacy of varenicline, combination nicotine replacement therapies, and motivational interviewing in smokers who are homeless
    Skelton, Eliza
    Lum, Alistair
    Cooper, Lucy E.
    Barnett, Emma
    Smith, Julie
    Everson, Arlene
    Machart, Jane
    Baker, Amanda
    Halpin, Sean
    Nielssen, Olav
    Bonevski, Billie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 40 - 41
  • [32] Neuropsychiatric adverse events of bupropion treatment: a brief update
    Soyka, M
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2004, 8 (04) : 251 - 254
  • [33] Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol
    Cimolai, Nevio
    CLINICAL MEDICINE & RESEARCH, 2019, 17 (3-4) : 90 - 96
  • [34] Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children
    Wintzell, Viktor
    Brenner, Philip
    Halldner, Linda
    Rhedin, Samuel
    Gong, Tong
    Almqvist, Catarina
    JAMA PEDIATRICS, 2025,
  • [35] Risk of neuropsychiatric adverse events among montelukast users
    Eworuke, Efe
    Haug, Nicole
    Mosholder, Andrew
    Cocoros, Noelle
    Bradley, Marie
    Pennap, Dinci
    Dee, Elizabeth C.
    Toh, Sengwee
    Prestine, Ella
    Petrone, Andrew
    Kim, Ivone
    Ma, Yong
    Lyons, Jennifer G.
    Sansing, Veronica V.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 7 - 8
  • [36] In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT
    Kress, Catherine M.
    Obi, Ngozi U.
    Prochazka, Allan V.
    ANNALS OF INTERNAL MEDICINE, 2017, 167 (06) : JC31 - JC31
  • [37] NEUROPSYCHIATRIC SYMPTOMS IN SMOKERS QUITTING WITH VARENICLINE OR PLACEBO: A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PILOT STUDY
    Garza, D.
    Murphy, M.
    Tseng, L. -J.
    Riordan, H.
    Chatterjee, A.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [38] Use of Varenicline vs. Bupropion and Risk of Psychiatric Adverse Events
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 389 - 389
  • [39] Varenicline and smokers with mental illnesses
    Lasser, Karen E.
    Boyd, J. Wesley
    LANCET, 2008, 372 (9645): : 1218 - 1219
  • [40] Varenicline: risk of neuropsychiatric AEs examined
    Reactions Weekly, 2015, 1544 (1) : 13 - 13
12345